Sage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.com

StockNews.com cut shares of Sage Therapeutics (NASDAQ:SAGE) from a hold rating to a sell rating in a report published on Monday.

Other analysts have also recently issued reports about the stock. Wedbush reissued a “neutral” rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Canaccord Genuity Group reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, February 12th. HC Wainwright reiterated a “neutral” rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Bank of America assumed coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.81.

Sage Therapeutics Price Performance

NASDAQ SAGE opened at $7.07 on Monday. The stock’s 50 day simple moving average is $7.41 and its 200 day simple moving average is $6.72. The firm has a market cap of $442.73 million, a PE ratio of -1.07 and a beta of 0.20. Sage Therapeutics has a one year low of $4.62 and a one year high of $13.47.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm’s quarterly revenue was up 78.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.80) EPS. As a group, equities analysts expect that Sage Therapeutics will post -3.52 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaQuest LLC acquired a new stake in Sage Therapeutics in the first quarter worth $32,000. Picton Mahoney Asset Management grew its holdings in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares during the period. Headlands Technologies LLC bought a new stake in shares of Sage Therapeutics in the 1st quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new stake in Sage Therapeutics during the 4th quarter worth $49,000. Finally, Ieq Capital LLC acquired a new stake in Sage Therapeutics during the 4th quarter worth $57,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.